FDA
-
-
-
-
-
-
-
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
-
-
-
-
-
-
-
KOMZIFTI added to NCCN guidelines for relapsed AML treatment
-
-
-
-
-
-
-
Kura Oncology and Kyowa Kirin begin trial combining cancer drugs for AML
-
-
-
-
-
-
-
Guggenheim Starts Kura Oncology (KURA) at Neutral
-
-
-
-
-
-
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
-
-
-
-
-
-
-
Kura Oncology Reports First Quarter 2025 Financial Results
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

